However, patients with baseline brain metastasis were excluded by the RELAY trial, and the efficacy of ramucirumab combined with erlotinib in EGFR-mutated NSCLC patients with brain metastasis was not clear (34). Here, EGFR is linked to non-small cell lung carcinoma.